In Segment C, members will get ABBV-744 and oral navitoclax. In Section D, members will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. For all circulation cytometry experiments, 10,000 cells for each replicate ended https://abbv-744-and-other-brd4-i81356.p2blogs.com/31213677/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results